Discovery of CNS Penetrant CXCR2 Antagonists for the Potential Treatment of CNS Demyelinating Disorders.

Heng Xu,Hongfu Lu,Zhongmiao Xu,Linbo Luan,Chengyong Li,Yan Xu,Kelly Dong,Jinqiang Zhang, Xiong Li, Yvonne Li,Gentao Liu,Sophie Gong,Yong-Gang Zhao,Ailian Liu,Yueting Zhang,Wei Zhang,Xin Cai,Jia-Ning Xiang,John D Elliott,Xichen Lin

ACS medicinal chemistry letters（2016）

引用 15|浏览31

暂无评分

摘要

Structure-activity relationship exploration of the historical biarylurea series led to the identification of novel CNS penetrant CXCR2 antagonists with nanomolar potency, favorable PK profile, and good developability potentials. More importantly, the key compound 22 showed efficacy in a cuprizone-induced demyelination model with twice daily oral administration, thereby supporting CXCR2 to be a potential therapeutic target for the treatment of demyelinating diseases such as multiple sclerosis.

查看译文

关键词

CNS penetration,CXCR2 antagonists,cuprizone model,demyelinating disorders,demyelination and remyelination,diarylureas,multiple sclerosis

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要